![](/wp-content/uploads/2024/06/Screenshot-2024-06-11-at-4.28.51%E2%80%AFPM.png)
$599
Syntis Bio Launches with Oral Anti-Obesity Therapy; Akero Initiates Ph3 SYNCHRONY Outcomes Trial in MASH; Merck Initiates H2H Ph3 Oral PCSK9i Trial; Nanexa Doses First Patient in New QM Liraglutide Study
A series of cardiometabolic-related news items have been observed from Syntis Bio, Akero Therapeutics, Merck, and Nanexa AB. Below, FENIX provides highlights and insights for the respective news items.